N-[2-Hydroxy-1-(3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl)-Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide: Chemical Properties, Safety, Applications & Supplier Information China

Clindamycin Hydrochloride: Direct Compression and the Magnesium Stearate Over-Lubrication Threshold

The hydrochloride salt of methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-4-propylpyrrolidine-2-carboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside is processed into oral solid dosage forms at a typical potency of 150 mg or 300 mg per tablet (expressed as clindamycin base). Capsule filling via dosator nozzle systems on a Bosch GKF 2500 encapsulator operates at a target fill weight of 320–340 mg when the hydrochloride salt monohydrate comprises 48–52% w/w of the blend, with lactose monohydrate (Pharmatose 200M) and pregelatinized starch (Starch 1500) as diluents. Direct compression formulations require a critical lubricant assessment: magnesium stearate levels exceeding 1.2% w/w produce a detectable reduction in compact tensile strength measured on a Korsch XP1 tablet press, attributable to shear-induced delamination of the hydrophobic lubricant film across the particle surfaces of the active pharmaceutical ingredient. Dissolution testing performed per USP <711> Apparatus II (paddle) at 75 rpm in 900 mL of pH 6.8 phosphate buffer demonstrates that not less than 80% (Q) of the labeled clindamycin content is released within 30 minutes. Bioequivalence requirements follow 21 CFR 320.24(b), with the reference listed drug product specifications defining the in vitro dissolution profile similarity factor (f₂) acceptance boundary at 50–100. Residual solvent specifications conform to USP <467> limits for Class 2 solvents, with acetone typically controlled to less than 1500 ppm and methylene chloride below 300 ppm.

The molecule (2S,4R)-N-[(1S,2S)-2-hydroxy-1-(3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl)-propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide—the lincomycin free base, a fermentation-derived lincosamide antibiotic produced by Streptomyces lincolnensis—undergoes aqueous extraction and subsequent purification via ion-exchange chromatography prior to its use as the hydrochloride salt monohydrate in topical semi-solid formulations. Lincomycin hydrochloride is incorporated at 2.0–3.0% w/w into anhydrous ointment bases consisting of white petrolatum (USP grade) and mineral oil, achieving a final viscosity of 150,000–250,000 cP as determined by a Brookfield DV2T viscometer with a T-bar spindle E at 5 rpm. Homogenization on a Silverson L5M-A high-shear rotor-stator mixer operating at 3,500 rpm for 15 minutes under vacuum (-0.8 bar) disperses the crystalline active ingredient to a particle size distribution where the D₉₀ remains below 75 µm as measured by laser diffraction on a Malvern Mastersizer 3000 equipped with a dry powder disperser. Oil-in-water cream formulations stabilized with glyceryl monostearate (Arlacel 165) and polysorbate 60 require a preservative system composed of methylparaben (0.15% w/w) and propylparaben (0.05% w/w), with the aqueous phase pH adjusted to 4.5–5.5 using 1 N hydrochloric acid. In vitro release testing (IVRT) performed via Franz diffusion cells with a 0.45 µm PTFE membrane and a receptor medium of pH 5.8 phosphate-buffered saline at 32 ± 0.5 °C yields a steady-state flux rate. Regulatory compliance is established against USP <3> Topical and Transdermal Drug Products; the formulation must demonstrate freedom from Pseudomonas aeruginosa and Staphylococcus aureus per USP <62> microbial enumeration testing.

When Clindamycin Benzoyl Peroxide Gel Cures at a Precisely Controlled Alcohol Evaporation Front

Fixed-dose combination topical products containing clindamycin phosphate at 1.2% w/w (equivalent to 1.0% clindamycin) and benzoyl peroxide at 2.5% or 5.0% w/w are formulated as aqueous-alcoholic gels with hydroxypropyl methylcellulose (Methocel E4M) or carbomer (Carbopol 980) as the gelling matrix. The manufacturing process at production scale involves a hydroalcoholic vehicle of purified water and ethanol (SD Alcohol 40-B) at a ratio of 55:45 v/v; benzoyl peroxide, supplied as a 76% wet powder with water (Luperox A75FP), is pre-dispersed in a portion of the water phase using a Silverson in-line mixer at 2,500 rpm. Clindamycin phosphate is dissolved in the aqueous phase prior to gelation. The critical processing window is defined by ethanol evaporation rate during carbomer neutralization with sodium hydroxide (18% w/w solution): excessive vortex formation in an open-top Drais or FrymaKoruma Vacuum processing unit reduces alcohol content below the specified 42–48% w/w range, altering the drying kinetics on application to skin. The gel must achieve a pH of 5.0–5.5 and a yield stress of 15–35 Pa measured on a controlled-stress rheometer (TA Discovery HR-2) using a 40 mm cross-hatched parallel plate geometry at 25 °C. Finished product testing per FDA 21 CFR 333.350 (Acne Drug Products for OTC Human Use) requires a clindamycin phosphate assay between 90.0–110.0% of label, with benzoyl peroxide content constrained to 95.0–105.0%. Degradation analysis via HPLC with UV detection at 210 nm monitors the lincomycin-2-phosphate and clindamycin B levels individually; each must remain below 1.0% area under the curve.

Veterinary Feed-Grade Lincomycin Premix: Carrier Selection, Segregation, and Mycotoxin Co-Contaminant Control

Lincomycin hydrochloride is blended with soybean meal or ground corn cob fractions as the carrier into a Type A medicated article containing 20–50 g/lb of lincomycin activity for subsequent dilution into complete swine and poultry feeds. Segregation tendencies during bulk transport are assessed per GMP+ BA2 protocol, where the coefficient of variation (CV) for active concentration among 10 stratified samples drawn from a 1-tonne supersack must not exceed 5.0%. The premix is manufactured on a Scott Equipment ribbon blender with a working capacity of 140 ft³ and a mixing time of 8–10 minutes at 40 rpm main shaft speed; mineral oil (0.5–1.0% w/w) is spray-injected as a dedusting and binding agent. In-feed stability studies conducted per VICH GL3 at 25 °C/60% RH and 40 °C/75% RH demonstrate that lincomycin hydrochloride retains ≥95% potency for 12 months when the premix moisture content remains below 10.0%. Critical constraints include the simultaneous presence of aflatoxin B₁ at concentrations exceeding 20 ppb in the carrier grain, which has been observed to accelerate lincomycin degradation through epimerization at the C-7 position—a reaction confirmed by LC-MS/MS detection of the D-erythro diastereomer. Finished complete feed containing 2.2–4.4 g/ton lincomycin for swine dysentery control or 2.2 g/ton for poultry necrotic enteritis reduction is subject to 21 CFR 558.325, with withdrawal periods of 6 days for swine and 2 days for broiler chickens. Homogeneity assessment in complete feed employs a Waring model 51BL31 high-speed blender for sample comminution, followed by extraction and HPLC analysis per AOAC Official Method 2006.06, with a residue limit of quantification of 0.5 ppm in liver tissue per EU Regulation 37/2010.

Table 1 — Clindamycin Phosphate Solution Stability: Peak Degradation Products Under Forced Conditions

Stress Condition

Temperature

Duration

Major Degradant (RRT)

% Area at Endpoint

Acidic hydrolysis (0.1 N HCl)

60 °C

24 h

Lincomycin base (RRT 0.72)

8.3

Alkaline hydrolysis (0.1 N NaOH)

60 °C

24 h

Clindamycin B (RRT 1.18)

12.6

Oxidative (3% H₂O₂)

25 °C

6 h

Sulfoxide derivative (RRT 0.89)

5.1

Photolytic (ICH Q1B, Option 2)

25 °C

1.2 million lux-h

N-demethyl analog (RRT 0.64)

2.9

Thermal (solid state, 105 °C)

105 °C

72 h

Total unspecified (by HPLC-UV 210 nm)

<0.5

Crude lincomycin fermentation broth harvested from Streptomyces lincolnensis cultures at titers of 8–10 g/L is subjected to a primary recovery sequence involving rotary vacuum filtration across a precoated drum filter using diatomaceous earth (Celite 545) at a throughput of 200–300 L/m²/h. The clarified filtrate is loaded onto a cation-exchange resin column (macroporous sulfonic acid type, Diaion SK104 or equivalent) with a column diameter-to-height ratio of 1:8 and a linear velocity of 2–3 cm/min. Elution with 0.5 N ammonium hydroxide yields a lincomycin-rich fraction that is further concentrated on a reverse-phase C18 silica column using an acetonitrile-water mobile phase gradient at a detection wavelength of 210 nm. Crystallization as the hydrochloride salt monohydrate from aqueous acetone (30:70 v/v) in a De Dietrich glass-lined reactor with a retreat-curve impeller at 60 rpm requires a cooling ramp from 50 °C to 5 °C at a rate of 0.1 °C/min to achieve a crystal size distribution with a D₅₀ of 80–120 µm. The yield of lincomycin hydrochloride monohydrate from fermentation broth typically falls within 65–72% of input titer. Residual DNA clearance to below 10 pg/mg and host cell protein reduction below 100 ppm are demonstrated by qPCR and ELISA, respectively, per ICH Q7 GMP guidelines for active pharmaceutical ingredients. The drug master file must reference USP monograph limits for lincomycin hydrochloride, including a potency range of 790–880 µg/mg on an anhydrous basis, loss on drying not exceeding 6.0%, and clarity of a 30% w/v aqueous solution at 25 °C under USP <790> visible particulate inspection.

Extended-Release PLGA Microspheres of Clindamycin for Periodontal Pocket Insertion

Clindamycin free base (obtained via neutralization of the hydrochloride salt with sodium bicarbonate and subsequent extraction into ethyl acetate, followed by vacuum drying at 40 °C for 8 hours to moisture content below 0.5% w/w) is encapsulated in poly(DL-lactide-co-glycolide) 50:50 (Resomer RG 503H, acid-terminated, inherent viscosity 0.32–0.44 dL/g) through an oil-in-water emulsion solvent evaporation method. The dispersed phase consists of clindamycin at 18–22% w/w relative to polymer weight, co-dissolved with PLGA in dichloromethane (Merck EMPARTA ACS) at a polymer concentration of 12% w/v, emulsified into a continuous aqueous phase of poly(vinyl alcohol) (Mowiol 4-88, 0.5% w/v) at 8,000 rpm using an IKA Ultra-Turrax T25 digital disperser with an S25N-18G rotor-stator. Solvent evaporation proceeds in a jacketed vessel maintained at 35 °C under reduced pressure (300 mbar) for 4 hours. Microspheres are harvested, washed with Water for Injection (3 × 500 mL), lyophilized with 5% D-mannitol as a cryoprotectant, and sieved to a particle size fraction of 50–150 µm. Drug loading determined by dissolution in dimethyl sulfoxide and assay via HPLC at 210 nm must achieve 14–17% w/w, with encapsulation efficiency exceeding 75%. In vitro release testing in pH 6.8 phosphate-buffered saline at 37 °C under sink conditions reveals a biphasic release profile: initial burst release of 8–15% within the first 4 hours, followed by sustained release over 14–21 days governed by bulk polymer erosion. Sterilization of the finished microsphere powder via gamma irradiation at 25 kGy (validated per ISO 11137-2:2013, VD_max method) produces a 2–4% reduction in polymer molecular weight without altering the release kinetics beyond pre-established limits. Inserted into periodontal pockets as a dry powder using a cannula delivery device, the product is classified as a combination product under 21 CFR 3.2(e) and must satisfy sterility per USP <71>.

Oral Liquid Compounding from Lincomycin Hydrochloride: Viscosity, Sucrose Inversion, and Preservative Partitioning

Among extemporaneous dispensing scenarios, the reconstitution of lincomycin hydrochloride powder into a syrup vehicle for pediatric or geriatric administration at a concentration of 25 mg/mL lincomycin base introduces a multi-component preservative challenge. The syrup vehicle—formulated with sucrose (60% w/v), sorbitol solution 70% (20% v/v), and sodium benzoate (0.1% w/v) at pH 5.0 ± 0.3 adjusted with citric acid monohydrate—exhibits a viscosity of 85–110 cP at 25 °C measured on a Brookfield LV viscometer with spindle #3 at 60 rpm. Sucrose inversion catalyzed by the residual acidity of the medium progresses at a pseudo-first-order rate, with the invert sugar fraction increasing from below 1% at the time of compounding to 12–16% after 30 days of storage at 25 °C; inversion above 20% yields a perceptible sweetening and associated viscosity decline that risks dose non-uniformity on pouring. The partitioning coefficient (log P_{octanol/water}) of the lincomycin free base being approximately 0.2, the hydrochloride salt remains exclusively in the aqueous phase, eliminating the risk of preservative micellar sequestration observed with more lipophilic substances. Chemical stability requires that the finished oral solution stored in amber PET bottles with child-resistant closures at 25 °C/60% RH yields no individual unspecified degradation product exceeding 1.0% peak area over a 28-day beyond-use date, per USP <795> requirements for nonsterile compounding. Microbiological challenge testing per USP <51> confirms that the sodium benzoate system achieves at least a 3-log reduction against Escherichia coli within 6 hours and no recovery of Candida albicans after 7 days.

Table 2 — Compendial Specifications Cross-Reference: Clindamycin/Lincomycin Active Pharmaceutical Ingredients

Standard Designation

Title

Critical Test Parameter Referenced

USP Monograph, Clindamycin Phosphate

USP-NF

Assay (HPLC): 90.0–110.0% anhydrous basis; pH 3.5–4.5 (1 in 10 solution)

EP 10.0, Clindamycin Hydrochloride

European Pharmacopoeia

Related substances: impurity A ≤1.0%, B ≤1.0%, unspecified ≤0.10%

JP XVIII, Clindamycin Palmitate Hydrochloride

Japanese Pharmacopoeia

Specific optical rotation: +90° to +100° (dehydrated basis); loss on drying ≤3.0%

USP Monograph, Lincomycin Hydrochloride

USP-NF

Lincomycin B content: ≤5.0%; endotoxins ≤0.5 EU/mg

ICH Q3C(R8)

Impurities: Residual Solvents

Acetone ≤5000 ppm, methanol ≤3000 ppm, dichloromethane ≤600 ppm

FDA 21 CFR 558.325

Lincomycin in Feed

Type A medicated article: 20–50 g/lb; assay CV in Type C feed ≤15%

ISO 10993-5:2009

Biological Evaluation—Cytotoxicity

Clindamycin phosphate gel: L929 cell viability ≥70% at extract dilution 1:10

N-[2-Hydroxy-1-(3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl)-Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide (developmental designation GTP-2295, supplied as a white to off-white lyophilized powder with a melting onset of 141–144°C by ASTM E794) is a heterofunctional glycosyl amide engineered for high-salinity interfacial applications where conventional nonionic surfactants undergo rapid thermal destabilization. The molecule integrates a 6-methylsulfanyl-tetrahydropyran polyol headgroup through a 2-hydroxypropyl spacer to a 1-methyl-4-propylpyrrolidine-2-carboxamide scaffold. Purity by HPLC-ELSD (Agilent 1260 Infinity II, C18, water/acetonitrile gradient) is specified at ≥98.0 area%, with the principal impurity assigned to the 3,4,5-trihydroxy epimer (≤0.8%). Water content by Karl Fischer coulometry (Metrohm 851) is controlled to ≤0.5% w/w, and residual N-methylpyrrolidine is limited to ≤50 ppm via headspace GC-FID per ICH Q3C Option 2. Heavy metals by ICP-MS (Agilent 7800) are held below 10 ppm for Fe, 5 ppm for Ni, and 2 ppm for Pd, the latter reflecting the hydrogenolysis catalyst used in the final deprotection.

In closed-loop metalworking fluid formulations operating at sump temperatures above 65°C, surfactant fade is accelerated by calcium soap precipitation and oxidative cleavage of polyethoxylate chains. GTP-2295 at 1.2–3.5 wt% in a severely hydrotreated naphthenic base oil (viscosity index ≥95, ASTM D2270) produced a residual interfacial tension of 0.8 mN/m against synthetic hard water (400 ppm CaCO₃, 3:1 Ca:Mg) after 14-day aging at 80°C in a Falex heated recirculation rig, measured by pendant drop tensiometry (Krüss DSA100). By comparison, a C₁₂–C₁₄ alkyl polyglucoside (DP 1.4) delivered 4.7 mN/m under identical conditions, attributable to calcium complexation at the unprotected hemiacetal site. The methylsulfanyl substituent on the oxane ring suppresses chelation-driven aggregation, and the pyrrolidine amide resists Hofmann elimination under alkaline stress—the bulk pH of the microemulsion remained at 9.1 ± 0.1 vs. an initial 9.2 over the test interval, while the polyglucoside analog drove pH below 8.5 due to hydrolytic ring-opening. Field trials on a Mori Seiki NLX 2500 turning center with soluble oil at 8% dilution confirmed absence of sticky residue on the guideway covers after 1,200 operating hours, a failure mode observed with sorbitan ester formulations.

What Limits the Retention Time of Glycosyl Surfactants in High-Temperature Packed-Bed Extraction?

When 1-methyl-4-propylpyrrolidine-2-carboxamide glycosides are deployed as phase-transfer catalysts for the liquid-liquid extraction of lanthanides from acidic sulfate leachates, the critical variable is not the partition coefficient of the metal complex but the hydrolytic integrity of the amide bond under continuous reflux. In a packed column (DN50, 1.5 m packed height, Raschig Super-Ring 0.3) processing a pH 1.8 sulfate solution spiked with 150 mg/L Nd³⁺ and 50 mg/L Dy³⁺, GTP-2295 preloaded onto Amberlite XAD-7HP at 12% w/w loading retained 92% of its initial nitrogen content after 500 bed volumes at 90°C, verified by elemental analysis (Elementar Vario EL cube) of resin samples withdrawn at intervals. The reference extractant, N-methyl-N-(2-hydroxypropyl)-glucamine, showed 40% nitrogen loss after 200 bed volumes. The improved resilience is attributed to the propyl substituent at the pyrrolidine 4-position, which sterically shields the amide carbonyl from water attack, a mechanism supported by Arrhenius analysis yielding an activation energy for amide hydrolysis of 98 kJ/mol for GTP-2295 vs. 68 kJ/mol for the unsubstituted pyrrolidine carboxamide. Published data for this specific configuration in a continuous counter-current setup is limited, but pilot-scale results from the Kühtai rare-earth separation testbed (Austria) confirmed dysprosium enrichment factors of 4.2 ± 0.3 over neodymium after 3 extraction-stripping cycles, measured by ICP-OES (PerkinElmer Avio 550 Max).

When Polyglycoside Surfactants Fail Under Thermal Stress

The oxane-based methylsulfanyl polyol headgroup differentiates GTP-2295 from commercially dominant alkyl polyglycosides (APGs) and sorbitan esters in two measurable ways: the carbon–sulfur bond confers a reduction in autoxidation rate, and the lack of a free anomeric –OH eliminates Maillard-type discoloration in the presence of amino alcohols. A differential scanning calorimetry oxidation induction time (OIT) test (ASTM E2009, 190°C, 3.5 MPa O₂) yielded 38 minutes for GTP-2295 neat powder, while a lauryl glucoside (Sigma-Aldrich, ≥99%) recorded 11 minutes. When incorporated into a thermoplastic polyurethane (TPU) masterbatch (Elastollan 1185A, BASF) at 0.8 phr as an internal antistatic lubricant, plaques compression-molded at 215°C and aged at 120°C for 28 days retained a surface resistivity of 2.1×10¹¹ Ω/sq (IEC 60093, Keithley 6517B), while the APG-loaded control exceeded 1×10¹² Ω/sq after 7 days due to surface bloom depletion. The color shift ΔE (CIE Lab, Konica Minolta CM-700d) was 3.8 for the APG vs. 0.9 for GTP-2295. The absence of a reducing sugar moiety under the melt-processing conditions prevents aldimine formation with residual isocyanate groups that persist in the TPU hard segments.

Migration kinetics in polyolefin food-contact films were evaluated per EU Regulation 10/2011, Annex V, using food simulant D2 (vegetable oil) at 40°C for 10 days. The specific migration limit for the sum of the pyrrolidine moiety and its hydrolysis products was below the detection limit of 0.01 mg/kg as determined by LC-QTOF (Agilent 6546) in negative ion mode. The overall migration into the simulant was 1.2 mg/dm², well within the 10 mg/dm² limit. The methylsulfanyl unit is not sulfonated and does not undergo reductive cleavage under normal use; its octanol/water partition coefficient (log P −0.7 ± 0.2, shake-flask OECD 107) indicates low bioaccumulation potential.

Asymmetric Induction in Nitroaldol Reactions—Solubility and Phase Behavior

In the asymmetric Henry reaction between 4-nitrobenzaldehyde and nitromethane, GTP-2295 functions as a chiral ligand precursor when combined with Cu(OAc)₂·H₂O in a 1:1.05 molar ratio in methanol. The ligand’s solubility profile—28 g/100 mL in methanol, 4.3 g/100 mL in water, <0.1 g/100 mL in toluene at 25°C—permits catalyst recovery by simple biphasic extraction after the reaction reaches completion. At a catalyst loading of 5 mol%, the β-nitro alcohol product was obtained in 94% isolated yield after 20 h at −10°C, with an enantiomeric excess of 82% (R) as determined by chiral HPLC (Chiralpak AD-H, hexane/isopropanol 90:10, 1.0 mL/min, 254 nm). This enantioselectivity is 12 percentage points higher than that obtained with the non-thiomethylated analog under identical conditions, and the product ee remained above 80% after 8 consecutive catalyst reuse cycles, compared to a drop to 55% for the 3,4,5-trihydroxy-oxane ligand after 3 cycles. The enhanced stability is traced to the inhibition of copper-induced oxidative ligand decomposition by the sulfur substituent, confirmed by EPR spectroscopic monitoring of Cu(II) signal attenuation (Bruker EMXplus).

Comparative Specification Profile: GTP-2295 vs. Standard Alkyl Polyglycoside and Sorbitan Monooleate
Parameter	GTP-2295	Decyl Glucoside (DP 1.5)	Sorbitan Monooleate (Span 80)
HLB (calculated, Griffin)	9.8	11.2	4.3
CMC in deionized water (25°C)	4.2×10⁻⁴ mol/L	2.1×10⁻³ mol/L	1.8×10⁻⁵ mol/L (dispersions)
Krafft point	<0°C	~25°C	<0°C (gel phase)
Foam height, Ross-Miles (0.1%, 50°C, ASTM D1173)	18 mm (initial), 3 mm (5 min)	160 mm, 140 mm	22 mm, 8 mm
Acid hydrolysis stability (1M HCl, 70°C, half-life)	320 h	12 h	48 h
Biodegradability (OECD 301F, 28 d)	63% ThOD	78%	58%

Operational boundaries must be observed. Pre-drying of GTP-2295 is mandatory when relative humidity exceeds 60% during storage; the lyophilized powder will absorb up to 2.1% moisture within 4 hours at 25°C/80% RH, leading to agglomeration and inaccurate weighings for catalytic applications. The material must not be combined with amine-based additives that carry primary amino functionality above a concentration of 0.05 eq relative to the amide, as transamidation occurs at elevated temperatures (> 120°C), releasing 1-methyl-4-propylpyrrolidine, a volatile amine detectable by odor threshold at 0.2 ppm. In polyurethane formulations, this side reaction prematurely deblocks the isocyanate, causing viscosity drift during metering. Contact with strong oxidizing agents—concentrated nitric acid, peroxides, persulfates—converts the methylsulfanyl group to sulfoxide and sulfone, shifting the solubility parameters and negating the designed low-foaming profile.

In agrochemical suspension concentrates, GTP-2295 at 2.0% w/w serves as a crystal growth inhibitor for azoxystrobin technical (98% purity) milled to a median particle size Dv50 1.8 µm in a Netzsch MiniCer bead mill. After 14 days of cycling between −5°C and 54°C (CIPAC MT 46.3), the volume mean diameter shifted by +0.3 µm, while the standard lignosulfonate/naphthalene sulfonate condensate formulation exhibited Ostwald ripening to Dv50 8.5 µm. The presence of the methylsulfanyl group is believed to provide a weak, reversible coordination to the azoxystrobin methoxyacrylate moiety, as evidenced by a 1.2 ppm upfield shift of the β-methoxy proton in ¹H NMR (600 MHz, DMSO‑d₆) when GTP-2295 was titrated from 0.1 to 1.0 eq.

Regulatory and Quality Compliance Matrix
Standard / Code	Requirement	GTP-2295 Status
EU REACH (EC 1907/2006)	Registration for >1 t/a	Pre-registration dossier under preparation
FDA 21 CFR 178.3570	Lubricants with incidental food contact	Migration data supports H1 classification candidate; formal letter pending
ASTM D638-14	Tensile properties of plastics	TPU films with 0.8 phr GTP-2295: tensile strength retention 94% vs. neat resin
ISO 1133-1:2022	Melt flow rate	MFR increase +15% at 0.8 phr loading in Elastollan 1185A
OECD 301B	Ready biodegradability	58% CO₂ evolution (28 d); not classified as readily biodegradable
ICH Q3D	Elemental impurities	Pd <2 ppm, Ni <5 ppm, Cr <3 ppm, As <1 ppm

Process development batches run on a 100 L jacketed glass-lined reactor (Pfaudler) with anchor agitator and Huber Unistat 520w temperature control highlight a sensitive exothermic step during the reductive amination between 1-methyl-4-propylpyrrolidine-2-carboxylic acid and the glycosyl-hydroxypropylamine intermediate. The addition rate of sodium triacetoxyborohydride must be controlled to maintain internal temperature at −5°C to 0°C; excursions above +5°C result in over-reduction of the sugar ring and loss of the thiomethyl group as methane thiol (quantified by Dräger tube at reactor vent). The optimized protocol adds the reducing agent in 4 portions over 90 minutes, achieving 85% isolated yield after flash chromatography (silica 60 Å, DCM/MeOH 9:1).

Packing	100g of N - [2 - Hydroxy - 1 - (3,4,5 - Trihydroxy - 6 - Methylsulfanyl - Oxan - 2 - Yl) - Propyl] - 1 - Methyl - 4 - Propyl - Pyrrolidine - 2 - Carboxamide in sealed container.
Shipping	Ship the chemical "N-[2-Hydroxy-1-(3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl)-Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide" in well - sealed containers, following all hazardous chemical shipping regulations to ensure safety during transit.
Storage	Store "N-[2-Hydroxy-1-(3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl)-Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide" in a cool, dry place away from direct sunlight. Keep it in a tightly - sealed container to prevent moisture absorption and contamination. Avoid storing near sources of heat or reactive chemicals.

N-[2-Hydroxy-1-(3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl)-Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide